CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 75 enrolled
Drug / intervention
OTO-201 (ciprofloxacin)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02511561
NCT02511561Phase 2Completed

A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration for Treatment of Otitis Externa

Otonomy, Inc.·interventional·Posted Jul 30, 2015·Updated Oct 19, 2020

In Brief

A Phase 2 clinical trial evaluating OTO-201 (ciprofloxacin) for Otitis Externa. Completed, enrolled 75 participants across 1 site.

Detailed Summary

This is a 1-month, multicenter, open-label study in subjects with unilateral otitis externa. Eligible subjects will receive a single dose of 6 mg OTO-201 to the affected ear. The study is designed to characterize safety, procedural factors and clinical effect of OTO-201 administered in subjects with otitis externa.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOtitis Externa
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 30, 2015
Enrollment StartJul 1, 2015
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.9 years ago

Interventions

OTO-201 (ciprofloxacin)drug